MediWound (MDWD) vs Regencell Bioscience (RGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MediWound (MDWD) has outperformed Regencell Bioscience (RGC) over the past year, losing 29.9% versus a loss of 60.1%. Over five years, RGC leads with a +1398.5% price change compared with -47.5% for MDWD. Regencell Bioscience is the larger company by market cap ($3.64 billion vs $161.9 million), about 22.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDWD | RGC |
|---|---|---|
| Share price | $12.54 | $7.35 |
| Market cap | $161.89M | $3.64B |
| 1-day change | +0.97% | -3.67% |
| YTD return | -32.07% | -65.00% |
| 1-year return | -29.94% | -60.14% |
| 5-year return | -47.47% | +1398.47% |
| EPS (TTM) | $-2.17 | $-0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-11.70M |
| 52-week high | $20.03 | $69.00 |
| 52-week low | $12.42 | $4.51 |
| Distance from 52-week high | -37.39% | -89.35% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +144.58% | — |
| Average volume | 84.67K | 199.19K |
| Shares outstanding | 12.91M | 495.88M |
| Employees | 121 | 10 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Regencell Bioscience is about 22.5 times larger than MediWound by market value ($3.64B vs $161.89M).
- MDWD has outperformed RGC by 30.2 percentage points over the past year.
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Health Care · Medicinal Chemicals and Botanical Products · 121 employees
About Regencell Bioscience
RGC stock →Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 10 employees
MDWD vs RGC FAQ
Which is bigger, MediWound or Regencell Bioscience?
Regencell Bioscience (RGC) is larger, with a market capitalization of $3.64B compared with $161.89M for MediWound (MDWD).
Which stock has performed better over the past year, MDWD or RGC?
MDWD returned -29.94% over the past 12 months, compared with -60.14% for RGC (price return, excluding dividends). Past performance does not predict future results.
Are MediWound and Regencell Bioscience in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.